高级检索

脑血康胶囊联合抗血小板治疗缺血性脑卒中的效果及对脑血流量的影响

陆翠燕, 潘伟锋, 邵妤, 曹雯

陆翠燕, 潘伟锋, 邵妤, 曹雯. 脑血康胶囊联合抗血小板治疗缺血性脑卒中的效果及对脑血流量的影响[J]. 实用临床医药杂志, 2020, 24(3): 40-43. DOI: 10.7619/jcmp.202003012
引用本文: 陆翠燕, 潘伟锋, 邵妤, 曹雯. 脑血康胶囊联合抗血小板治疗缺血性脑卒中的效果及对脑血流量的影响[J]. 实用临床医药杂志, 2020, 24(3): 40-43. DOI: 10.7619/jcmp.202003012
shu
LU Cuiyan, PAN Weifeng, SHAO Yu, CAO Wen. Effect of Naoxuekang Capsule combined with anti-platelet therapy on ischemic stroke and its influence on cerebral blood flow[J]. Journal of Clinical Medicine in Practice, 2020, 24(3): 40-43. DOI: 10.7619/jcmp.202003012
Citation: LU Cuiyan, PAN Weifeng, SHAO Yu, CAO Wen. Effect of Naoxuekang Capsule combined with anti-platelet therapy on ischemic stroke and its influence on cerebral blood flow[J]. Journal of Clinical Medicine in Practice, 2020, 24(3): 40-43. DOI: 10.7619/jcmp.202003012
shu

脑血康胶囊联合抗血小板治疗缺血性脑卒中的效果及对脑血流量的影响

  • 1. 上海市普陀区中医医院 药剂科, 上海, 200062;

  • 2. 上海市中医药大学附属岳阳中西医结合医院 药剂科, 上海, 200437

基金项目: 

上海市科技厅科研项目(2015SZ010382)

详细信息

  • 中图分类号: R743.3

Effect of Naoxuekang Capsule combined with anti-platelet therapy on ischemic stroke and its influence on cerebral blood flow

  • 1. Department of Pharmacy, Putuo District Hospital of Traditional Chinese Medicine, Shanghai, 200062;

  • 2. Pharmacy Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437

摘要

    摘要
  • 摘要: 目的 探讨脑血康胶囊联合抗血小板治疗缺血性脑卒中的效果及对脑血流量的影响。 方法 选取本院收治的533例缺血性脑卒中患者为研究对象,根据患者治疗方案分为3组, 217例应用阿司匹林的患者纳入阿司匹林组, 184例应用脑血康胶囊的患者纳入脑血康组, 132例应用阿司匹林联合脑血康胶囊的患者纳入联合组。比较3组患者的临床疗效、美国国立卫生院卒中量表(NIHSS)评分、血小板聚集率、脑血流速度、脑血流量。 结果 联合组治疗总有效率为91.67%, 显著高于阿司匹林组的82.95%以及脑血康组的80.98%(P < 0.05)。治疗1、2、3个月时,联合组的NIHSS评分、血小板聚集率均低于阿司匹林组和脑血康组(P < 0.05); 联合组的平均脑血流速度、平均脑血流量均高于阿司匹林组和脑血康组(P < 0.05)。阿司匹林组与脑血康组的治疗总有效率、NIHSS评分、血小板聚集率、脑血流速度、脑血流量比较无显著差异(P > 0.05)。 结论 脑血康胶囊的抗血栓效果与阿司匹林相似,缺血性脑卒中患者联合使用脑血康胶囊和阿司匹林有利于改善神经功能,增加脑血流量,提高治疗效果。
    Abstract: Objective To explore curative effect of Naoxuekang Capsule combined with anti-platelet therapy on ischemic stroke(IS)and its influence on cerebral blood flow(CBF). Methods A total of 533 IS patients who were admitted to the hospital were enrolled as study objects. According to different treatment plans, they were divided into three groups. A total of 217 patients treated with aspirin were included in aspirin group, 184 patients treated with Naoxuekang Capsules were included in Naoxuekang group, and 132 patients treated with aspirin and Naoxuekang Capsules were included in combination group. The clinical curative effect, score of National Institutes of Health Stroke Scale(NIHSS), platelet aggregation rate, cerebral blood flow velocity and cerebral blood flow volume were compared among the three groups. Results The total response rate of treatment in combination group was 91.67%, which was significantly higher than 82.95% in aspirin group and 80.98% in Naoxuekang group(P < 0.05). After 1-, 2- and 3- month treatment, NIHSS score and platelet aggregation rate in combination group were lower than those in aspirin group and Naoxuekang group(P < 0.05). The cerebral blood flow velocity and cerebral blood flow volume in combination group were higher than those in aspirin group and Naoxuekang group(P < 0.05). There were no significant differences in total response rate of treatment, NIHSS score, platelet aggregation rate, cerebral blood flow velocity or - cerebral blood flow volume between aspirin group and Naoxuekang group(P > 0.05). Conclusion The antithrombotic effect of Naoxuekang Capsule is similar to that of aspirin. The combined application of Naoxuekang Capsule and aspirin in IS patients can improve nerve function, increase cerebral blood flow volume, and improve curative effect.
    • HTML全文
    • 参考文献(20)

  • Randolph S A. Ischemic stroke[J]. Workplace Health Saf, 2016,64(9): 444-448.

    Radu R A, Terecoasă E O, Băjenaru O A, et al. Etiologic classification of ischemic stroke: Where do we stand[J]. Clin Neurol Neurosurg, 2017, 8(159): 93-106.

    Radak D, Katsiki N, Resanovic I, et al. Apoptosis and acute brain ischemia in ischemic stroke[J]. Curr Vasc Pharmacol, 2017, 15(2): 115-122.

    Feng R, Badgeley M, Mocco J, et al. Deep learning guided stroke management: a review of clinical applications[J]. J Neurointerv Surg, 2018, 10(4): 358-362.

    Rabinstein A A. Treatment of Acute Ischemic Stroke[J]. Continuum, 2017, 23(1): 62-81.
    毛全高. 水蛭素剂型研究进展[J]. 安徽医药, 2015, 19(12): 2250-2254.
    中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4): 246-257.
    李霞, 王炜, 赵仕琪, 等. 脑梗死患者COX-1及COX-2基因多态性与阿司匹林抵抗的相关性分析[J]. 中风与神经疾病杂志, 2019, 36(6): 488-492.

    Hao Q, Tampi M, O'Donnell M, et al. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis[J]. BMJ, 2018, 18(363): 5108.
    刘玉府, 王利红.人尿激肽原酶联合血小板抑制剂对高血压脑梗死大鼠凝血功能及神经功能的影响[J]. 中华实验外科杂志, 2016, 33(6): 1597-1600.
    赵华, 龚道恺. 阿司匹林片联合阿托伐他汀钙片治疗急性脑梗死的临床研究[J]. 中国临床药理学杂志, 2016, 32(21): 1934-1936.
    林子霖. 基于近15年文献分析探讨急性脑梗死的中医证治[D]. 广州: 广州中医药大学, 2014.
    韦维, 李国辉, 陈绚, 等. 注射用血栓通联合依达拉奉治疗缺血性脑卒中的临床疗效及对患者神经功能缺损和生活质量的影响[J]. 实用临床医药杂志, 2017, 21(7): 140-142.

    Müller C, Haase M, Lemke S. 9884 Hemorrhagic Stroke Associated with High aPTTs Following Thrombolytic Therapy and Heparin or Hirudin[J]. Parasitol Res, 2017, 116(1): 313-325.

    Nowak G, Schrör K. Hirudin-the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond[J]. A historical piece, 2017, 98(1): 116-119.

    Zhang J, Lan N. Hirudin variants production by genetic engineered microbial factory[J]. Biotechnol Genet Eng Rev, 2018, 34(2): 261-280.

    Liu Y, Yang J, Wang J, et al. Test of hirudin activity by tracking the binding of hirudin to thrombin in the presence of BS3 cross-linking[J]. Blood Coagul Fibrinolysis, 2015, 26(7): 823-826.

    Sheffield W P, Eltringham L J, Bhakta V. A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss[J]. BMC Biotechnol, 2018,18(1): 21-26.
    李红, 吴黎黎, 高青, 等. 水蛭素对脑出血大鼠蛋白酪氨酸激酶2/信号转导和转录激活因子3信号通路的影响[J]. 中国脑血管病杂志, 2017, 14(12): 638-643.
    张锐, 宋郁喜, 黄荣等. 灯盏花素联合依达拉奉治疗缺血性脑卒中的临床疗效及对患者神经功能缺损和生活质量的影响[J]. 实用临床医药杂志, 2017, 21(3): 15-18.
    • 相关文章
    • 施引文献(6)

  • 期刊类型引用(6)

    1. 郑春利，李朋菊. 奥拉西坦联合倍他司汀治疗卒中后眩晕对患者脑血流及血清AngⅡ、PDGF-BB水平的影响. 医学临床研究. 2024(11): 1669-1671+1675 . 百度学术
    2. 阎早芳，孙瑞华，陈燕芬，虞康达. 水蛭单方制剂治疗缺血性脑血管病的网状Meta分析. 中国中药杂志. 2023(04): 1108-1115 . 百度学术
    3. 杨华荣，郑江环. CYP2C19基因型检测指导抗血小板治疗缺血性脑卒中的疗效及对预后的影响. 实用临床医药杂志. 2023(22): 31-36 . 本站查看
    4. 王媛媛，王博，刘媛媛，郭岩松，李猛，董巧云. 缺血性脑卒中病人外周血中NDRG2蛋白、 mTOR含量与预后的相关性分析. 蚌埠医学院学报. 2023(12): 1709-1713 . 百度学术
    5. 岳瑞华. 尿激酶静脉溶栓联合抗血小板治疗对急性轻型脑卒中患者的效果. 临床医学. 2022(12): 110-112 . 百度学术
    6. 李俊杰，张永顺，温倩茹. 阿司匹林联合氯吡格雷治疗穿支动脉闭塞性脑梗死患者的效果及对血清FIB、Hcy水平影响. 中外医学研究. 2021(33): 152-154 . 百度学术

    其他类型引用(0)

    • 资源附件(0)
计量
  • 文章访问数:  281
  • HTML全文浏览量:  50
  • PDF下载量:  12
  • 被引次数: 6
出版历程
  • 收稿日期:  2019-11-15

目录

摘要
HTML全文
    参考文献(20)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计